Your browser doesn't support javascript.
loading
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Sha, Fushen; Okwali, Michelle; Alperovich, Anna; Caron, Philip C; Falchi, Lorenzo; Hamilton, Audrey; Hamlin, Paul A; Horwitz, Steven M; Joffe, Erel; Khan, Niloufer; Kumar, Anita; Matasar, Matthew J; Moskowitz, Alison J; Noy, Ariela; Owens, Colette; Palomba, Lia M; Rodriguez-Rivera, Ildefonso; Straus, David; von Keudell, Gottfried; Zelenetz, Andrew D; Yahalom, Joachim; Dogan, Ahmet; Schöder, Heiko; Seshan, Venkatraman E; Salles, Gilles; Younes, Anas; Batlevi, Connie L.
Afiliación
  • Sha F; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Okwali M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alperovich A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hamilton A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hamlin PA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Joffe E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Khan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Moskowitz AJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Owens C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Palomba LM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rodriguez-Rivera I; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Straus D; Currently employed at NEXT Oncology / Texas Oncology, San Antonio, TX, USA.
  • von Keudell G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yahalom J; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Dogan A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schöder H; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Seshan VE; Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Salles G; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Blood Cancer J ; 12(2): 29, 2022 02 10.
Article en En | MEDLINE | ID: mdl-35145059
ABSTRACT
Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center. Approximately half of patients (137, 46%) underwent initial observation and half (158, 54%) immediate treatment radiation alone (n = 108), systemic treatment alone (n = 29), or combined modality treatment (n = 21). Median follow-up was 8.4 years (range 0.3-17.2), and 10-year overall survival (OS) was 87.2%. OS was similar between initially-observed and immediately-treated patients (hazard ratio [HR] 1.25, 95% CI 0.67-2.36, p = 0.49). For patients receiving radiation alone, 5-year OS was 98.0%. Patients selected for systemic therapy alone had high-risk baseline features and had shorter OS than patients treated with radiation alone (HR 3.38, 95% CI 1.29-8.86, p = 0.01). Combined modality treatment did not yield superior survival compared with radiation alone (P > 0.05) but was associated with better progression-free survival (HR 0.36, 95% CI 0.14-0.90, p = 0.03). The rate of transformation increased steadily over time and was 4.2% at 5 years and 10.8% at 10 years. This modern-era analysis rationalized the role of initial observation in patients with early-stage FL although patients receiving radiation therapy also demonstrate excellent outcome.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Folicular Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Folicular Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...